Navigation Links
Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
Date:4/19/2009

ed through 13 weeks after the booster infusion (p < 0.001). The PROVENGE booster infusions occurred from 0.2 to 5.5 years (median 1.1 years) after the week four dose.

Data is being presented in a session titled, "Cancer Vaccines: Human Studies" in a presentation titled, "Antigen presenting cell activation in sipuleucel-T and long-term immune responses in prostate cancer trial" today at 8:00 AM MDT at the 100th Annual Meeting of the Association for Cancer Research in Denver, Colorado.

"We are encouraged to see that CD54 upregulation in APCs is maintained after boosting in men with androgen-dependent prostate cancer," said David Urdal, chief scientific officer of Dendreon. "This pattern of CD54 upregulation suggests that the first dose 'primes' the immune system for subsequent 'memory' responses and is consistent with that observed in our studies of men with androgen-independent disease where the cumulative CD54 upregulation dose correlated with survival. We also are encouraged by these data which suggest that the immune response generated by PROVENGE is durable for a year or more after initial treatment and that it can be maintained following boosting."

Study Design

The study, known as PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11, is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and biologic activity of PROVENGE in men with non-metastatic androgen-dependent prostate cancer who have had a prostate-specific antigen (PSA) recurrence following surgical removal of the prostate. A total of 176 patients at 19 sites in the United States were randomized two to one to receive PROVENGE or placebo following a three-month course of hormonal therapy. Patients were then followed with serial PSA measurements to evaluate the impact of PROVENGE on PSA and PSADT (PSA doubling time). At the time of biochemical progression, defined as a PSA of 3 ng/mL or
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
2. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
3. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
4. Dendreon Reports Third Quarter 2008 Financial Results
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
7. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
8. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
9. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
10. Dendreon Reports First Quarter 2008 Financial Results
11. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Prinz Law Office has announced the launch of several ... secure legal services in the current economic climate. ... the opportunity to finance legal services over a period ... any equity in their start-up companies. The second ... fixed montly payment arrangements over 6 to 12 month ...
(Date:12/14/2009)... The third edition of Infusion Nursing: ... by the Infusion Nurses Society (INS), includes Totect(®), ... Anthracyclines are a group of chemotherapy medications including ... used in the treatment of various types of ... According to the INS publication: "In September 2007, ...
(Date:12/14/2009)... of Brookfield Engineering’s Powder Flow Tester – helping Brookfield move ... footprint and more compact design. , ... ... US-based thermoforming company, has completed the delivery of Brookfield Engineering’s ... to a plastic enclosure with a smaller footprint and more ...
(Date:12/11/2009)... December 2009 -- Researchers have discovered a new explanation for ... more excess copies of a certain gene, the more serious ... and it is suspected that it is the amount of ... are being published in the American Journal of Human ... group of Guy Froyen connected to VIB, a life sciences ...
Breaking Biology Technology:The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2Amount of gene surplus determines severity of mental retardation in males 2
... next-generation Tissue Ligating ... ... a,leading surgical device company, has been named a 2007 Innovator of ... Starion for its newest Tissue Ligating Shears, the TLS3,which uses the ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ), ... commercializing proprietary product candidates for the treatment,of ... Evan M. Levine,ADVENTRX,s chief executive officer, is ... Annual Growth Conference on Wednesday,September 19th, 2007 ...
... development targeting glucagon ... collaboration to identify antisense drugs to inhibit ... Conference call webcast Thursday, September 13, 9:45 a.m. EDT at ... http://www.isispharm.com , CARLSBAD, Calif., Sept. 13 ...
Other Biology Technology:Society of Laproendoscopic Surgeons Names Starion Instruments 2007 Innovator of the Year 2ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners' Fifth Annual Growth Conference 2Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 2Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 3Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 4Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 5
(Date:12/13/2009)... led by Yale University researchers has used nanosensors ... the first time. Their findings, which appear December ... Nature Nanotechnology , could dramatically simplify the way ... diseases. , The teamled by Mark ... Applied Science, and Tarek Fahmy, an associate professor ...
(Date:12/11/2009)... orientalis species of wild apples that could be an ... East and Central Asia. A new study comparing the ... from Georgia and Armenia with previously collected varieties originating ... establishes a core collection that will make M. ... communities. , To identify and record the genetic diversity ...
(Date:12/11/2009)... associate professor of anthropology at the University of Arizona, ... to understand how violence shapes the health of those ... her and her colleagues, research," Documenting the health consequences ... Kenya: A conceptual framework," is currently published in a ... in collaboration with the British medical journal the ...
Breaking Biology News(10 mins):Scientists use nanosensors for first time to measure cancer biomarkers in blood 2Understanding apples' ancestors 2UA-led study grapples with health effects of low-intensity warfare 2Caraco Pharmaceutical Laboratories Ltd Announces Change to Executive Team as Jitendra N Doshi Assumes Position of CEO 53013 1Caraco Pharmaceutical Laboratories Ltd Announces Change to Executive Team as Jitendra N Doshi Assumes Position of CEO 53013 2Human Genome Sciences Announces Pricing of Public Offering of Common Stock 13237 1Human Genome Sciences Announces Pricing of Public Offering of Common Stock 13237 2Human Genome Sciences Announces Pricing of Public Offering of Common Stock 13237 3Teens May Not Benefit from Pap Tests 53010 1Teens May Not Benefit from Pap Tests 53010 2Teens May Not Benefit from Pap Tests 53010 3
... ever, but the amount of data to be analyzed ... that genome sequence analysis can be made interactive and ... of data. , Researchers from the Department of ... their entry at the Supercomputing ,08 High Performance Computing ...
... In a study in the advance online edition of ... College of Medicine describe a technique for looking more ... a gene, DNA, being read into a message, mRNA. The ... genes are switched on inappropriately, causing disease. , The ...
... to biofuel crops can increase or decrease greenhouse gas emissions, ... used, University of Illinois researchers report this month. , The ... planting new biofuel crops can influence the carbon content of ... Global Change Biology Bioenergy . , Plants use the ...
Other Biology News:PNNL researchers earn top honors at Supercomputing conference 2PNNL researchers earn top honors at Supercomputing conference 3Einstein researchers develop technique to count messages made by single genes 2Replacing corn with perennial grasses improves carbon footprint of biofuels 2Replacing corn with perennial grasses improves carbon footprint of biofuels 3
...
... series of robotic workstations is designed for ... is the ideal automation platform for routine ... laboratory procedures, improving throughput, process consistency and ... MiniPrep software allows you to control the ...
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
...
Biology Products: